ABC Arbitrage SA Purchases Shares of 26,939 Telix Pharmaceuticals Limited (NASDAQ:TLX)

Key Points

• ABC Arbitrage SA purchased 26,939 shares of Telix Pharmaceuticals Limited valued at around $451,000 in the first quarter.
• Several research firms issued favorable ratings for Telix Pharmaceuticals, with William Blair and Wedbush both reissuing "outperform" ratings and price objectives of $22.00 and $23.00, respectively.
• Telix Pharmaceuticals stock is currently down 8.0%, with a trading price of $12.26 and a twelve-month range between $12.10 and $30.36.

ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 26,939 shares of the company's stock, valued at approximately $451,000.

Separately, Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at $170,000.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. Finally, HC Wainwright assumed coverage on shares of Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 target price on the stock.

Telix Pharmaceuticals Stock Down 3.7%

TLX traded down $0.44 during trading on Friday, hitting $11.34. 155,231 shares of the stock traded hands, compared to its average volume of 64,757. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The firm has a 50-day moving average of $15.59 and a 200 day moving average of $16.74. Telix Pharmaceuticals Limited has a 12-month low of $11.34 and a 12-month high of $30.36.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.